Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Trading 11-22 15:52:42 EST

56.21

+0.99

+1.80%

High56.40	Low55.22	Vol498.47M
Open55.22	D1 Closing55.21	Amplitude2.14%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O8.44B	T/O Rate--	Tradable Shares0.00
P/B5.431127	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":56.209396,"timestamp":1732308762041,"preClose":55.2147,"halted":0,"volume":498469134,"delay":0,"changeRate":0.018015,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0.994698,"latestTime":"11-22 15:52:42 EST","open":55.215595,"high":56.396885,"low":55.215595,"amount":8439968724.605174,"amplitude":0.021394,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.431127,"peRate":-50.989175,"turnoverRate":0.015757,"increases":396,"decrements":172,"flats":13,"marketCap":1475244060573.3125,"floatMarketCap":1323716123305.5625},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2485160652","title":"Jefferies says market nears short term “peak RFK negativity\", Vaccine makers up","url":"https://stock-news.laohu8.com/highlight/detail?id=2485160652","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485160652?lang=en_us&edition=fundamental","pubTime":"2024-11-23 04:16","pubTimestamp":1732306589,"startTime":"0","endTime":"0","summary":"Investing.com --Shares of Moderna Inc   were up roughly 7% at $41, while those of Pfizer Inc were up nearly 2%. Jefferies analysts said Investor sentiment around Moderna Inc could be nearing a short-term low, amid recent concerns tied to vaccine transparency and structural issues might start to ease.The analysts referred to fears surrounding Robert F. Kennedy Jr.’s presidential bid—particularly over vaccine-related rhetoric—may have heightened market anxiety.However, they see a potential bounce in Moderna’s stock, with Kennedy unlikely to pursue drastic measures against vaccines and transparency efforts possibly benefiting the company in the long term.So far this year, Moderna stock has lost nearly 60% value.Moderna continues to face structural challenges, including high operating expenses, risks around flu/COVID-19 combo vaccine approvals, and limited visibility on profitability through 2028. Yet, upcoming catalysts could provide upside.Robinhood's top attorney Gallagher rules out SEC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jefferies-says-market-nears-short-201629260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","BK4599","SG9999001176.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","LU1894683348.USD","BK4568","LU0170899867.USD","BK4581","BK4585","LU0225284248.USD","LU0321505439.SGD","LU0868494617.USD","BK4535","LU0306807586.USD","IE00BBT3K403.USD","LU0289739699.SGD","LU0321505868.SGD","SG9999002224.SGD","LU0234572021.USD","SG9999003800.SGD","LU0122379950.USD","LU1057294990.SGD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","IE0002270589.USD","MRNA","BK4532","BK4551","BK4592","LU1894683264.USD","LU1883839398.USD","BK4139","PFE","BK4548","LU0456855351.SGD","SG9999013999.USD","BK4501","LU0985481810.HKD","LU1066051498.USD","BK4534","LU0225771236.USD","SG9999002232.USD","BNTX","SGXZ57979304.SGD","LU0306806265.USD","SG9999001176.USD","SG9999011175.SGD","BK4533","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2485417218","title":"Xencor: Plamotamab NHL Data Leads To RA Program Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485417218","media":"seekingalpha","labels":["Product Release","analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485417218?lang=en_us&edition=fundamental","pubTime":"2024-11-23 03:00","pubTimestamp":1732302053,"startTime":"0","endTime":"0","summary":"Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00.Initiation of ","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178482079/image_2178482079.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178482079/image_2178482079.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4739704-xencor-plamotamab-nhl-data-leads-to-ra-program-advancement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","XNCR"],"gpt_icon":0},{"id":"2485909142","title":"Trending: Halozyme Drops Bid for Evotec","url":"https://stock-news.laohu8.com/highlight/detail?id=2485909142","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485909142?lang=en_us&edition=fundamental","pubTime":"2024-11-23 02:50","pubTimestamp":1732301400,"startTime":"0","endTime":"0","summary":"1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros . Dow Jones & Co. owns Factiva. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"2485008213","title":"FDA Accepts Bayer's Application for Label Expansion of Nubeqa","url":"https://stock-news.laohu8.com/highlight/detail?id=2485008213","media":"Zacks","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485008213?lang=en_us&edition=fundamental","pubTime":"2024-11-23 02:36","pubTimestamp":1732300560,"startTime":"0","endTime":"0","summary":"Bayer BAYRY announced that the FDA has accepted its supplemental new drug application  for Nubeqa .The sNDA is seeking label expansion of Nubeqa in combination with androgen deprivation therapy  for the treatment of patients with metastatic hormone-sensitive prostate cancer .Year to date, shares of Bayer have lost 44.9% against the industry’s growth of 4.8%.Nubeqa is an androgen receptor inhibitor  with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation and AR-mediated transcription.The sNDA submitted is based on positive results from the late-stage ARANOTE study. Results showed that Nubeqa plus ADT significantly reduced the risk of progression or death in patients with metastatic mHSPC when compared to placebo plus ADT.We note that Nubeqa is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for those with non-metastatic castration-resistant prostate cancer .A potential FDA approval of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cCc8LMcWOu520tkUFivbqw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cCc8LMcWOu520tkUFivbqw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-bayers-application-label-183600814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","SG9999001176.USD","LU0058720904.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU1057294990.SGD","LU0321505439.SGD","LU0321505868.SGD","SG9999002232.USD","LU1066053197.SGD","BK4531","LU1023059063.AUD","SGXZ57979304.SGD","LU0456855351.SGD","BK4581","BK4007","BK4588","LU0225284248.USD","LU1066051498.USD","BK4592","IE00BBT3K403.USD","BK4165","BK4534","BCR","BK4533","IE0002270589.USD","LU0868494617.USD","SG9999003800.SGD","SG9999011175.SGD","HCM","BAYRY","LU0985481810.HKD","LU0289739699.SGD","IE00B19Z3581.USD","PFE","ADT","BK4568","IE00B19Z3B42.SGD","IE00BLSP4239.USD","LU1894683348.USD","SG9999002224.SGD","IE000M9KFDE8.USD","BK4505","BK4599","LU1894683264.USD","SG9999001176.SGD","LU0170899867.USD","BK4192","CYTK"],"gpt_icon":1},{"id":"2485294082","title":"Lexicon Pharmaceuticals (LXRX) Receives a Hold from Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2485294082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485294082?lang=en_us&edition=fundamental","pubTime":"2024-11-23 01:45","pubTimestamp":1732297511,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Stringer from Needham maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report). The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-receives-a-hold-from-needham?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-receives-a-hold-from-needham?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485429136","title":"MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2485429136","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485429136?lang=en_us&edition=fundamental","pubTime":"2024-11-23 01:25","pubTimestamp":1732296300,"startTime":"0","endTime":"0","summary":"As Bitcoin heads toward $100,000, it looks like three tiny biotechs are hoping to emulate the success of MicroStrategy, the software company whose stock has gone into orbit as it plows money into the cryptocurrency.In just the past week, Acurx Pharmaceuticals, Hoth Therapeutics, and Enlivex Therapeutics have announced plans to invest up to $1 million each in Bitcoin. That is, of course, an infinitesimal amount compared with MicroStrategy, whose balance-sheet holdings of 331,200 coins are now worth about $32.8 billion, one-third of its more than $95 billion market capitalization.MicroStrategy stock is up nearly 600% so far this year.Investors seem to realize that none of them are the next MicroStrategy. Only Hoth's shares got a modest pop this week, rising about 6% following its Bitcoin announcement. And all three stocks are down sharply this year, with Hoth tumbling 40% and Enlivex and Acurx each plunging more than 65%.Though the price is surging now, with a gain of almost 50% in the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03042","BK1611","09008","09439","ACXP","BK4007","BK4563","09042","MSTR","83042","03439","BK4585","HOTH","BK4139","03008","BTC.USD.HKCC","ENLV","BK4588","BK4601","BK4594","BK4539"],"gpt_icon":1},{"id":"2485742291","title":"Moderna up 8% as Jefferies says market is close to 'peak RFK negativity'","url":"https://stock-news.laohu8.com/highlight/detail?id=2485742291","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485742291?lang=en_us&edition=fundamental","pubTime":"2024-11-23 01:24","pubTimestamp":1732296283,"startTime":"0","endTime":"0","summary":"hapabapa Moderna  is up ~8% in Friday trading after company management said that Robert F. Kennedy Jr. potentially heading up HHS under the next Trump administration is not likely to lead to vaccines being pulled from the market. In a note, Jefferies analyst Michael Yee noted that while Kennedy Jr.'s nomination may have caused some investors anxiety, it is highly unlikely he would do \"anything draconian.\" Moderna's management made the comments Nov. 21 at the Jefferies London Healthcare Conference.  While some view the market as \"nearing short term ‘peak RFK negativity,'\" Yee added that others remain concerned about Moderna's profitability and structural issues. Jefferies has a hold rating on the stock with a $50 price target .","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4322475-moderna-up-8-jefferies-says-market-close-peak-rfk-negativity","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4533","BK4501","BK4585","BK4588","BK4568","BK4534","BK4532","BK4551","MRNA","BK4548"],"gpt_icon":1},{"id":"2485299726","title":"Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2485299726","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485299726?lang=en_us&edition=fundamental","pubTime":"2024-11-23 01:12","pubTimestamp":1732295578,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics, Inc.  saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE  for 11 euro  per share in cash, implying a fully diluted equity value of 2.0 billion euro.This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.The company expects revenue between $970 million and $1.02 billion  and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.Also Read: US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000. Helen Torley, CEO of Halozyme, explained that although the merger would","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1IYy6DehlWrM_QK5gaYrTw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1IYy6DehlWrM_QK5gaYrTw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4121","LU0053671581.USD","HALO","EVO"],"gpt_icon":0},{"id":"2485236296","title":"FDA posts observations from previous Regeneron facility inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=2485236296","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485236296?lang=en_us&edition=fundamental","pubTime":"2024-11-23 01:00","pubTimestamp":1732294811,"startTime":"0","endTime":"0","summary":"The FDA posted a summary of observations made from the Agency’s inspection of a Regeneron (REGN) facility in Ireland that was conducted from March ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-posts-observations-from-previous-regeneron-facility-inspection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-posts-observations-from-previous-regeneron-facility-inspection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2106854487.HKD","BK4585","LU2362540622.SGD","LU0889565916.HKD","LU2362541273.HKD","LU0289739699.SGD","LU0058720904.USD","LU2362541513.USD","LU0053666078.USD","LU2023250504.SGD","LU2468319806.SGD","LU1917777945.USD","LU0882574055.USD","LU0823416689.USD","LU2089984988.USD","LU1974910355.USD","BK4588","LU0320765992.SGD","REGN","LU0109394709.USD","LU0114720955.EUR","BK4139"],"gpt_icon":0},{"id":"2485962852","title":"Cautious Outlook on Moderna Amid Structural Challenges and Long-term Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2485962852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485962852?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:55","pubTimestamp":1732294518,"startTime":"0","endTime":"0","summary":"Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-moderna-amid-structural-challenges-and-long-term-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-moderna-amid-structural-challenges-and-long-term-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4532","BK4534","BK4585","BK4568","BK4139","BK4588","MRNA","BK4548","BK4501","BK4551"],"gpt_icon":0},{"id":"2485296284","title":"Moderna up as Jefferies suggests ‘peak RFK negativity’ may have been reached","url":"https://stock-news.laohu8.com/highlight/detail?id=2485296284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485296284?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:55","pubTimestamp":1732294515,"startTime":"0","endTime":"0","summary":"Jefferies hosted a fireside meeting with Moderna (MRNA) management, where the company noted that COVID vaccines are currently not mandated and ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-up-as-jefferies-suggests-peak-rfk-negativity-may-have-been-reached?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-up-as-jefferies-suggests-peak-rfk-negativity-may-have-been-reached?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4551","BK4532","BK4585","BK4139","BK4588","BK4501","BK4533","MRNA","BK4534","BK4568"],"gpt_icon":0},{"id":"2485956432","title":"BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2485956432","media":"Reuters","labels":["Shareholding Changes","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485956432?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:38","pubTimestamp":1732293520,"startTime":"0","endTime":"0","summary":"BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees** Lexicon Pharmaceuticals' LXRX.O shares rise 6.3% to 82 cents** Co says it plans to cut about 60% of its workforce effective Dec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT10N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Shareholding Changes,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485129286","title":"Corcept Shares Rise More Than 60% in Three Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2485129286","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485129286?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:32","pubTimestamp":1732293120,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym , which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters and the trend is likely to continue in 2025.The company is also making good progress with its promising set of pipeline candidates.Factors Driving CORT Stock in the Given Time Frame. Corcept’s top line solely comprises product sales from Korlym. The drug has been a consistent revenue driver for the company since approval. Sales of the drug increased 42.1% year over year to $493.2 million in the first nine months of 2024, owing to the strong demand and a record number of patients receiving the medication.Owing to the strong performance, CORT increased its annual revenue guidance for Korlym concurrently with third-quarter results. The company now expects total reven","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-shares-rise-more-60-163200157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CSTL","IMCR","LU0566484027.USD","CORT","BK4196","BK4505","BK4139","LU1559883803.SGD","SPRO","BK4532"],"gpt_icon":0},{"id":"2485295111","title":"Lexicon price target lowered to $4 from $6 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2485295111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485295111?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:30","pubTimestamp":1732293031,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Lexicon (LXRX) to $4 from $6 and keeps a Buy rating on the shares. The company announced that fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-lowered-to-4-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-lowered-to-4-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485932772","title":"Lexicon Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $4 From $6","url":"https://stock-news.laohu8.com/highlight/detail?id=2485932772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485932772?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:28","pubTimestamp":1732292890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nAZN2O2P0E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485292599","title":"Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2485292599","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485292599?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:28","pubTimestamp":1732292880,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO shares have lost 25.1% in the past three months compared with the industry’s decline of 17.7%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages.NVO Stock Underperforms the Industry, Sector & the S&P 500. However, the company’s strong fundamentals and the untapped nature of the obesity market make us believe that the setback is temporary. Long-term investors are advised not to be spooked by the current declining trend of the stock price as strong demand for Ozempic and Wegovy, coupled with NVO’s efforts to expand the drugs’ indications, exhibit significant potential in the future. Shares of Novo Nordisk have surged more than 260% in the past five years over the past five years. Total revenues jumped 90.3% on a reported basis, while the net profit margin consistently exceeded 31%, reaching a five-year high of 36% in 2023.Howeve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisk-plunges-25-3-162800656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0097036916.USD","LU0354030438.USD","SG9999001176.SGD","BK4599","LLY","LU2324357040.USD","LU2361045086.USD","LU0109391861.USD","LU0061475181.USD","LU1267930730.SGD","LU1804176565.USD","LU2237438978.USD","LU1127390331.HKD","LU0708995401.HKD","SGXZ81514606.USD","VKTX","SG9999015952.SGD","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","LU0820561909.HKD","LU0198837287.USD","NVO","IE00BJLML261.HKD","SG9999001176.USD","LU2265009873.SGD","LU2491049909.HKD","LU1057294990.SGD","AMGN","LU1551013425.SGD","BK4139","LU1061106388.HKD","LU2112291526.USD","LU1868836591.USD","LU0238689110.USD","LU0109394709.USD","SG9999015945.SGD","IE00BJT1NW94.SGD","LU0689472784.USD","LU0320765059.SGD","LU0154236417.USD","LU1712237335.SGD","LU0889565916.HKD","LU0006306889.USD","BK4532","LU2461242641.AUD","LU2491050154.USD","LU2468319806.SGD","SGXZ31699556.SGD","LU0203201768.USD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2485294516","title":"Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2485294516","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485294516?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:23","pubTimestamp":1732292580,"startTime":"0","endTime":"0","summary":"Replimune GroupREPL announced that it has submitted a biologics license application  to the FDA forits lead pipeline candidate, RP1, in combination withBristol Myers’BMY blockbuster immuno-oncology drug Opdivo  to treat adult patients with anti-PD1 failed advanced melanoma. The regulatory filing has been made under the FDA’s Accelerated Approval pathway. In response to the encouraging news, the stock rose 19.4% in the after-market hours on Thursday. The stock is also rising today during the pre-market hours.RP1 is based on a proprietary strain of herpes simplex virus, engineered and genetically armed with a fusogenic protein  and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.REPL’s RP1 BLA Submission Supported by Robust Study Data. Replimune’s BLA submission for RPI, in combination with Bristol Myers’ Opdivo, for the advanced melanoma indication is supported by positive top-line res","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/replimune-stock-rallies-bla-filing-162300397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU1057294990.SGD","BK4585","SG9999011175.SGD","LU1868836591.USD","BK4007","IE00BFTCPJ56.SGD","IE0009355771.USD","LU1066053197.SGD","IE00BLSP4452.SGD","BK4505","IE0002270589.USD","LU0170899867.USD","LU0234572021.USD","LU0306806265.USD","SG9999002224.SGD","LU1032466523.USD","BK4559","LU2242646821.SGD","IE00BLSP4239.USD","LU0985481810.HKD","LU1718418525.SGD","SG9999013999.USD","IE00BSNM7G36.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","HCC","SG9999002232.USD","BMY","LU1670711040.USD","LU0868494617.USD","BK4588","LU1261432733.SGD","PFE","LU1093756168.USD","LU1883839398.USD","LU1430594728.SGD","BK4139","REPL","LU0237698245.USD","ALLO","LU1585245621.USD","LU1894683348.USD","SG9999001176.SGD","IE00B19Z3581.USD","IE0002141913.USD","SGXZ57979304.SGD","BK4581","LU0289739699.SGD","LU2360032135.SGD"],"gpt_icon":1},{"id":"2485293404","title":"Anixa rises as board approves Bitcoin as a treasury reserve asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2485293404","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485293404?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:16","pubTimestamp":1732292167,"startTime":"0","endTime":"0","summary":"da-kuk Cancer drug developer Anixa Biosciences  traded higher on Friday after the company's board of directors approved the purchase of Bitcoin as a treasury reserve asset to diversify its financial position. \"With Anixa's strong balance sheet and excess cash, this strategic decision aims to diversify the company's treasury holdings while positioning Anixa to benefit from the potential long-term value of digital assets,\" the company said.  \"Our decision about Bitcoin is an additional approach to prudent financial management, enabling greater shareholder value,\" CEO Amit Kumar added. CFO Mike Catelani said that Bitcoin is a valuable addition to the company's treasury management strategy, given its recognition as a mainstream asset class. Additionally, the company reiterated its commitment to the ongoing stock buyback program, which it said implied its commitment to improve shareholder value.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157581483/image_2157581483.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157581483/image_2157581483.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4322153-anixa-stock-rises-bitcoin-added-treasury","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["US3Y.BOND","BK4588","US6M.BOND","US30Y.BOND","BK1611","03439","03008","US2Y.BOND","BK4601","03042","US12M.BOND","US10Y.BOND","83042","ANIX","09042","US5Y.BOND","09439","US7Y.BOND","09008","BK4139","BK4585","BK4594"],"gpt_icon":1},{"id":"2485581293","title":"Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store","url":"https://stock-news.laohu8.com/highlight/detail?id=2485581293","media":"seekingalpha","labels":["Policy And Regulatory","analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485581293?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:07","pubTimestamp":1732291623,"startTime":"0","endTime":"0","summary":"Moderna, Inc.'s stock has plummeted over 75% in 2024, driven by disappointing earnings, reduced revenue forecasts, and now the threat of a vaccine skeptic, RFK Jr.'s potential confirmation to lead HHS","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182853884/image_1182853884.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182853884/image_1182853884.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4739650-moderna-fresh-blow-rfk-hhs-tough-2025-may-be-in-store","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory,analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4534","BK4139","BK4532","MRNA","BK4568","BK4588","BK4551","BK4548","BK4585","BK4533","BK4501"],"gpt_icon":1},{"id":"2485293157","title":"Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2485293157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485293157?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:05","pubTimestamp":1732291508,"startTime":"0","endTime":"0","summary":"Evotec (EVO) issued the following comment on the withdrawn non-binding offer: “Evotec SE has taken notice of the statement made by Halozyme (HALO) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-takes-notice-of-halozyme-withdrawal-convicted-in-standalone-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-takes-notice-of-halozyme-withdrawal-convicted-in-standalone-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HALO","EVO","LU0053671581.USD","BK4139","BK4121"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}